Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection
Authors:
- 1 September 1993
- journal article
- research article
- Published by Wiley in Journal of Molecular Recognition
- Vol. 6 (3) , 101-109
Abstract
We synthesized one V3 peptide each from HTLV‐IIIB, Thai A and Thai B, conjugating then to the T cell epitope of the env region, and we also synthesized a p17 protein peptide of the gag region (HGP‐30). These peptide were then coupled to 8‐lysine copolymers using N‐succinimidyl maleimido carboxylate (Mr = ca 60 000). We designated this the branched lysine oligopeptide method. The large peptide complexes constructed from these four macromolecular peptide were used with aluminium hydroxide or complete Freund's adjuvant to immunize mice and rabbits four times. ELISA assay with aluminium hydroxide or complete Freund's adjuvant to immunize mice and rabbits four times. ELISA assay showed high titres of anti‐peptide antibodies to each V3loop peptide and the HGP‐30 peptide. Strong inhibition of CD4+ dependent cell fusion was obtained with these antisera when IIIb, Thai A and Thai B strains of human immunodeficiency virus (HIV) were used. Strong anti‐fusion inhibition was also observed with two other HIV strains. In addition, an increase of the anti‐HIV effect was observed when we used sera obtained by multicomponent vaccine immunization. The same kind of inhibition was also observed in p24 assay systems using these immunized antisera. Activation of IL‐2 production in lymphocytes was observed in p24 assay systems using these immunized antisera. Activation of IL‐2 production in lymphocytes was observed in mice immunized with this vaccine. These results suggest that immunization with macromolecular peptide complexes can result in strong immunogenicity towards HIV‐1.Keywords
This publication has 32 references indexed in Scilit:
- Vaccine Protection of Chimpanzees Against Challenge with HIV-1-Infected Peripheral Blood Mononuclear CellsScience, 1992
- Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.Journal of Experimental Medicine, 1991
- Safety and Immunogenicity of a Genetically Engineered Human Immunodeficiency Virus VaccineThe Journal of Infectious Diseases, 1991
- Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.Proceedings of the National Academy of Sciences, 1991
- The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in HumansAnnals of Internal Medicine, 1991
- HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.Proceedings of the National Academy of Sciences, 1990
- Immune response and epitope mapping of a candidate hiv‐1 p17 vaccine hgp30Journal of Clinical Laboratory Analysis, 1990
- Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.Proceedings of the National Academy of Sciences, 1988
- Second Conserved Domain of gp120 Is Important for HIV Infectivity and Antibody NeutralizationScience, 1988
- Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.Proceedings of the National Academy of Sciences, 1987